NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.03. The biotechnology company earned $0.24 million during the quarter, compared to analysts' expectations of $7 million. View Adaptimmune Therapeutics' Earnings History.

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

7 analysts have issued 12 month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $4.15 to $8.00. On average, they expect Adaptimmune Therapeutics' stock price to reach $6.03 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Media headlines about ADAP stock have trended negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Adaptimmune Therapeutics.

Adaptimmune Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,740,000 shares, an increase of 13.7% from the January 15th total of 1,530,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is currently 0.9 days. Approximately 2.0% of the shares of the company are sold short. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), I-Mab (BDTX), NanoString Technologies (NSTG), Twist Bioscience (TWST), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), AVITA MED LTD/S (RCEL), DBV TECHNOLOGIE/S (DBVT) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Second Sight Medical Products (EYES), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Micron Technology (MU) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (4.10%), Renaissance Technologies LLC (1.40%), Man Group plc (1.04%), Polygon Management Ltd. (0.82%), Partnervest Advisory Services LLC (0.03%) and Raymond James & Associates (0.03%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Elliot Norry, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Peter W Sonsini, Rafael Amado, Ravi Viswanathan and William C Bertrand, Jr. View Institutional Ownership Trends for Adaptimmune Therapeutics.

ADAP stock was sold by a variety of institutional investors in the last quarter, including Man Group plc and Marshall Wace LLP. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, Rafael Amado and William C Bertrand, Jr. View Insider Buying and Selling for Adaptimmune Therapeutics.

ADAP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Polygon Management Ltd., Baillie Gifford & Co., Partnervest Advisory Services LLC and Raymond James & Associates. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Lawrence M Alleva, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $3.98.

Adaptimmune Therapeutics has a market capitalization of $416.67 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]